Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Doximity (DOCS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), Doximity (DOCS – Research Report) and ArriVent BioPharma, Inc. (AVBP – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cytokinetics (CYTK)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Cytokinetics today and set a price target of $107.00. The company’s shares closed last Friday at $60.41.
According to TipRanks.com, Rahimi is a 5-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $93.77, representing a 52.8% upside. In a report issued on February 24, RBC Capital also maintained a Buy rating on the stock with a $101.00 price target.
See today’s best-performing stocks on TipRanks >>
Doximity (DOCS)
In a report released today, Ryan Halsted from RBC Capital maintained a Buy rating on Doximity, with a price target of $44.00. The company’s shares closed last Friday at $25.34, close to its 52-week low of $22.96.
According to TipRanks.com, Halsted is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Doximity with a $41.13 average price target, implying a 57.8% upside from current levels. In a report issued on February 25, TipRanks – Google also upgraded the stock to Buy with a $26.00 price target.
ArriVent BioPharma, Inc. (AVBP)
In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on ArriVent BioPharma, Inc., with a price target of $33.00. The company’s shares closed last Friday at $23.43.
According to TipRanks.com, Nochomovitz is a 3-star analyst with an average return of
ArriVent BioPharma, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $43.38, representing a 70.7% upside. In a report issued on March 6, Guggenheim also maintained a Buy rating on the stock with a $45.00 price target.
